CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation boost may extend life for limited-spread stomach and esophageal cancers
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2 negative esophageal or stomach cancer that has spread to only a few spots in the body. About 314 participants will receive either chemotherapy alone or chemotherapy plus radiation. T…
Matched conditions: CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can help shrink tumors in people with esophageal or gastroesophageal junction cancer before surgery. About 278 adults with stage II to IVA cancer will be e…
Matched conditions: CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC